Ergoteles’s Black Diamond Therapeutics BDTX Stock Holding History

Ergoteles’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-100,000	Closed	-$505K	–	116
2023 Q2	$505K	Buy	+100,000	New	+$204K	0.02%	639
2023 Q1	–	Sell	-20,212	Closed	-$36.4K	–	1271
2022 Q4	$36.4K	Sell	20,212 -30,135	-60%	-$54.3K	﹤0.01%	1320
2022 Q3	$85K	Sell	50,347 -59,653	-54%	-$184K	﹤0.01%	1400
2022 Q2	$271K	Buy	+110,000	New	+$256K	0.01%	1160
2021 Q4	–	Sell	-22,432	Closed	-$190K	–	1243
2021 Q3	$190K	Buy	+22,432	New	+$222K	0.01%	1021

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ergoteles's BDTX Position: Q3 2023 in Review

Ergoteles sold out of Black Diamond Therapeutics (BDTX) in Q3 2023, closing a stake of 100,000 shares — an estimated $505K sold.

Ergoteles first reported a position in BDTX in Q3 2021 and held it in 5 quarters. The position peaked at $505K in Q2 2023. 73 funds tracked by Wall St. Rank hold BDTX as of Q3 2023.

Ergoteles reported no remaining Black Diamond Therapeutics position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 100,000 Black Diamond Therapeutics shares in Q3 2023, an estimated $505K.
Ergoteles first reported a position in Black Diamond Therapeutics in Q3 2021 and held it in 5 quarters.
Ergoteles's Black Diamond Therapeutics position peaked at $505K in Q2 2023.
73 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.